<DOC>
	<DOCNO>NCT00615017</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , multi-center , dose-escalation study ass safety , tolerability , Pharmacokinetics Pharmacodynamics single multiple ascend intravenous infusion CytoFab ( AZD9773 ) adult patient severe sepsis .</brief_summary>
	<brief_title>AZD9773 Dose Escalation Study</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<criteria>Clinical evidence infection require treatment parenteral antibiotic Patients must meet multiple Systemic Inflammatory Response Syndrome ( SIRS ) criterion Patients must meet criterion cardiovascular and/or respiratory dysfunction Sepsis ( infection plus SIRS criterion ) must present prior organ dysfunction Moribund death consider imminent , patient expect survive 90 day underlie medical condition , classify Do Not Resuscitate Do Not Treat Patient attain MAP &gt; 60 mmHg measure via arterial line and/or Systolic Blood Pressure ( SBP ) &gt; 80 mmHg presence vasopressor iv fluids period ≥2 hour Receiving immunosuppressant , high dose steroid within 2 month provision inform consent Any history hypersensitivity reaction sheep product , latex , papain papaya , chymopapain previously administer antivenom manufacture use ovine serum , digoxin immune fab ( DigiFab™ , DIGIBIND® ) , crotalidae polyvalent immune fab ( ovine ) ( CroFab™ ) , sheep derive product . Treatment anti TumorNecrosisFactor ( antiTNF ) antibody within 8 week provision write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
</DOC>